Skip to main content

ORIGINAL RESEARCH article

Front. Mar. Sci.
Sec. Marine Biotechnology and Bioproducts
Volume 11 - 2024 | doi: 10.3389/fmars.2024.1480745

Diversity of Biological Activities of Crude Venom extracted from Five Species of South China Sea Anemones

Provisionally accepted
Panmin He Panmin He 1*Ming Li Ming Li 1*Jinxing Fu Jinxing Fu 1Yanling Liao Yanling Liao 1*Bo Yi Bo Yi 2*Bingmiao Gao Bingmiao Gao 1*
  • 1 Hainan Medical University, Haikou, China
  • 2 Department of Pharmacy, 928th Hospital of PLA Joint Logistics Support Force,, Haikou, Hainan, China

The final, formatted version of the article will be published soon.

    Developing novel, efficient, and safe peptide drugs from sea anemones has aroused great interest in countries around the world today. Sea anemones contain complex protein and peptide toxins, which determine the diversity of their biological activities. In this study, a variety of activities were assessed for crude venom extracted from five species of South China Sea anemones, including hemolytic, enzyme inhibition, anticancer, insecticidal, analgesic and lethal activities. The most toxic sea anemone was found to be Heteractis magnifica, which has high lethal activity in mice with an LD50 of 11.0 mg/kg. The crude venom of H. magnifica also exhibited a range of the most potent activities, including hemolytic, trypsin inhibitory, cytotoxic activity against U251 and A549 cells, insecticidal and analgesic activities. In addition, the crude venom of Stichodactyla haddoni was the most effective inhibitor of pepsin, and the crude venom of Heteractis crispa was extremely strong toxicity to HepG2 cells. These findings are of great significance for exploring the potential and application of South China Sea anemone resources, and are expected to provide new directions and possibilities for the development of novel anticancer drugs, analgesics and biopesticides.

    Keywords: Sea Anemones, Crude venom, Hemolytic activity, Enzyme inhibitory activity, Anticancer activity, Insecticidal activity, analgesic activity 1

    Received: 14 Aug 2024; Accepted: 16 Oct 2024.

    Copyright: © 2024 He, Li, Fu, Liao, Yi and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Panmin He, Hainan Medical University, Haikou, China
    Ming Li, Hainan Medical University, Haikou, China
    Yanling Liao, Hainan Medical University, Haikou, China
    Bo Yi, Department of Pharmacy, 928th Hospital of PLA Joint Logistics Support Force,, Haikou, Hainan, China
    Bingmiao Gao, Hainan Medical University, Haikou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.